



1. An anti-tumor pharmaceutical composition comprising a N-vanillyl fatty acid amide of formula (1):



wherein -CO-R group represents a saturated or unsaturated fatty acid residue containing from 14 to 32 carbon atoms.

2. An anti-melanoma pharmaceutical composition comprising a N-vanillyl fatty acid amide of formula (1):




wherein -CO-R group represents a saturated or unsaturated fatty acid residue containing from 14 to 32 carbon atoms.

3. The pharmaceutical composition according to claims 1 or 2 wherein the -CO-R group is a member selected from the group consisting of saturated fatty acid residues containing from 14 to 32 carbon atoms.

4. The pharmaceutical composition according to claim 3 wherein the -CO-R group is a member selected from the group consisting of myristic acid residue (C14), palmitic acid residue (C16) and stearic acid residue (C18).


5. The pharmaceutical composition according to claims 1 or 2 wherein the -CO-R group is a member selected from the group consisting of unsaturated fatty acid residues containing from 14 to 32 carbon atoms.
6. The pharmaceutical composition according to claim 5 wherein the -CO-R group is a member selected from the group consisting of unsaturated fatty acid residues having from 1 to 3 double bonds and containing 18 carbon atoms and unsaturated fatty acid residues having 4 or 5 double bonds and containing 20 carbon atoms.
7. The pharmaceutical composition according to claim 6 wherein the -CO-R group is a member selected from the group consisting of oleic acid residue (C18:1), ricinoleic acid residue (C18:1), linoleic acid residue (C18:2), linolenic acid residue (C18:3) and eleostearic acid residue (C18:3).
8. The pharmaceutical composition according to claim 6 wherein the -CO-R group is a member selected from the group consisting of arachidonic acid residue (C20:4) and eicosapentaenoic acid residue (C20:5).
9. The pharmaceutical composition according to claim 5 wherein the -CO-R group is a member selected from the group consisting of unsaturated fatty acid residues having four or more double bonds and containing 22, 24, 26, 28 or 32 carbon atoms.
10. The pharmaceutical composition according to claim 9, wherein the -CO-R group is 4,7,10,13,16,19-docosahexaenoic acid residue (C22:6).
11. A method for the treatment of tumor comprising administering a N-vanillyl fatty acid amide of formula (1):



wherein -CO-R group represents a saturated or unsaturated fatty acid residue containing from 14 to 32 carbon atoms.

12. The method according to claim 11 wherein the tumor is melanoma or leukemia.

13. Use of a N-vanillyl fatty acid amide of formula (1) in the manufacture of a medicament for the treatment of tumor:



wherein -CO-R group represents a saturated or unsaturated fatty acid residue containing from 14 to 32 carbon atoms.

14. The use according to claim 13 wherein the tumor is melanoma or leukemia.